Lehto, Taneli http://orcid.org/0000-0002-4428-1401
Zetterman, Teemu
Markkula, Ritva
Arokoski, Jari
Tikkanen, Heikki
Kalso, Eija
Peltonen, Juha E.
Funding for this research was provided by:
Finnish State Research Funding (TYH2017215)
Signe ja Ane Gyllenbergin Säätiö
Helsingin ja Uudenmaan Sairaanhoitopiiri (HUS 76/2018 § 11, HUS 174/2019 § 1)
Opetus- ja Kulttuuriministeriö
University of Helsinki including Helsinki University Central Hospital
Article History
Received: 19 September 2022
Accepted: 30 May 2023
First Online: 1 July 2023
Declarations
:
: The study was conducted in accordance with the Declaration of Helsinki and all subjects provided written consent. The study protocol was approved by the Ethics Committee of the Helsinki and Uusimaa Hospital District and it was registered in ClinicalTrials.gov (NCT03300635).
: Not applicable.
: Eija Kalso serves on the advisory boards of Orion Pharma and Pfizer and has received a lecture fee, unrelated to this work, from GSK. Ritva Markkula has received lecture fees, unrelated to this work, from Oy Eli Lilly Finland Ab. The other authors have no potential conflicts of interest to declare.